Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study.

Teerlink JR, Clarke CP, Saikali KG, Lee JH, Chen MM, Escandon RD, Elliott L, Bee R, Habibzadeh MR, Goldman JH, Schiller NB, Malik FI, Wolff AA.

Lancet. 2011 Aug 20;378(9792):667-75. doi: 10.1016/S0140-6736(11)61219-1.

PMID:
21856480
2.

The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial.

Cleland JG, Teerlink JR, Senior R, Nifontov EM, Mc Murray JJ, Lang CC, Tsyrlin VA, Greenberg BH, Mayet J, Francis DP, Shaburishvili T, Monaghan M, Saltzberg M, Neyses L, Wasserman SM, Lee JH, Saikali KG, Clarke CP, Goldman JH, Wolff AA, Malik FI.

Lancet. 2011 Aug 20;378(9792):676-83. doi: 10.1016/S0140-6736(11)61126-4.

PMID:
21856481
3.

Population pharmacokinetic-pharmacodynamic modeling of omecamtiv mecarbil, a cardiac myosin activator, in healthy volunteers and patients with stable heart failure.

Vu T, Ma P, Xiao JJ, Wang YM, Malik FI, Chow AT.

J Clin Pharmacol. 2015 Nov;55(11):1236-47. doi: 10.1002/jcph.538. Epub 2015 Jul 14.

PMID:
25951506
4.

Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and angina.

Greenberg BH, Chou W, Saikali KG, Escandón R, Lee JH, Chen MM, Treshkur T, Megreladze I, Wasserman SM, Eisenberg P, Malik FI, Wolff AA, Shaburishvili T.

JACC Heart Fail. 2015 Jan;3(1):22-9. doi: 10.1016/j.jchf.2014.07.009. Epub 2014 Nov 11.

5.

Improvement of cardiac function by a cardiac Myosin activator in conscious dogs with systolic heart failure.

Shen YT, Malik FI, Zhao X, Depre C, Dhar SK, Abarzúa P, Morgans DJ, Vatner SF.

Circ Heart Fail. 2010 Jul;3(4):522-7. doi: 10.1161/CIRCHEARTFAILURE.109.930321. Epub 2010 May 24.

6.

Myosin Activator Omecamtiv Mecarbil Increases Myocardial Oxygen Consumption and Impairs Cardiac Efficiency Mediated by Resting Myosin ATPase Activity.

Bakkehaug JP, Kildal AB, Engstad ET, Boardman N, Næsheim T, Rønning L, Aasum E, Larsen TS, Myrmel T, How OJ.

Circ Heart Fail. 2015 Jul;8(4):766-75. doi: 10.1161/CIRCHEARTFAILURE.114.002152. Epub 2015 May 29.

7.

Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure.

Liu LC, Dorhout B, van der Meer P, Teerlink JR, Voors AA.

Expert Opin Investig Drugs. 2016 Jan;25(1):117-27. doi: 10.1517/13543784.2016.1123248. Epub 2015 Dec 19.

PMID:
26587768
8.

Acute Treatment With Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study.

Teerlink JR, Felker GM, McMurray JJ, Ponikowski P, Metra M, Filippatos GS, Ezekowitz JA, Dickstein K, Cleland JG, Kim JB, Lei L, Knusel B, Wolff AA, Malik FI, Wasserman SM; ATOMIC-AHF Investigators.

J Am Coll Cardiol. 2016 Mar 29;67(12):1444-55. doi: 10.1016/j.jacc.2016.01.031.

9.

Cardiac myosin activation: a potential therapeutic approach for systolic heart failure.

Malik FI, Hartman JJ, Elias KA, Morgan BP, Rodriguez H, Brejc K, Anderson RL, Sueoka SH, Lee KH, Finer JT, Sakowicz R, Baliga R, Cox DR, Garard M, Godinez G, Kawas R, Kraynack E, Lenzi D, Lu PP, Muci A, Niu C, Qian X, Pierce DW, Pokrovskii M, Suehiro I, Sylvester S, Tochimoto T, Valdez C, Wang W, Katori T, Kass DA, Shen YT, Vatner SF, Morgans DJ.

Science. 2011 Mar 18;331(6023):1439-43. doi: 10.1126/science.1200113.

10.

Relative bioavailability, food effect, and safety of the single-dose pharmacokinetics of omecamtiv mecarbil following administration of different modified-release formulations in healthy subjects.

Palaparthy R, Banfield C, Alvarez P, Yan L, Smith B, Johnson J, Monsalvo ML, Malik F.

Int J Clin Pharmacol Ther. 2016 Mar;54(3):217-27. doi: 10.5414/CP202458.

11.

The myosin activator omecamtiv mecarbil: a promising new inotropic agent.

Nánási P Jr, Váczi K, Papp Z.

Can J Physiol Pharmacol. 2016 Feb 12:1-7. [Epub ahead of print]

PMID:
27322915
12.

Molecular effects of the myosin activator omecamtiv mecarbil on contractile properties of skinned myocardium lacking cardiac myosin binding protein-C.

Mamidi R, Gresham KS, Li A, dos Remedios CG, Stelzer JE.

J Mol Cell Cardiol. 2015 Aug;85:262-72. doi: 10.1016/j.yjmcc.2015.06.011. Epub 2015 Jun 20.

PMID:
26100051
13.

Cardiac myosin activation part 1: from concept to clinic.

Malik FI, Morgan BP.

J Mol Cell Cardiol. 2011 Oct;51(4):454-61. doi: 10.1016/j.yjmcc.2011.05.006. Epub 2011 May 17. Review.

PMID:
21616079
14.

A novel approach to improve cardiac performance: cardiac myosin activators.

Teerlink JR.

Heart Fail Rev. 2009 Dec;14(4):289-98. doi: 10.1007/s10741-009-9135-0. Review.

15.

Omecamtiv Mecarbil modulates the kinetic and motile properties of porcine β-cardiac myosin.

Liu Y, White HD, Belknap B, Winkelmann DA, Forgacs E.

Biochemistry. 2015 Mar 17;54(10):1963-75. doi: 10.1021/bi5015166. Epub 2015 Mar 4.

PMID:
25680381
16.

Left ventricular responses to acute changes in late systolic pressure augmentation in older adults.

Sweitzer NK, Hetzel SJ, Skalski J, Velez M, Eggleston K, Mitchell GF.

Am J Hypertens. 2013 Jul;26(7):866-71. doi: 10.1093/ajh/hpt043. Epub 2013 Mar 28.

17.
18.

A new approach to inotropic therapy in the treatment of heart failure: cardiac myosin activators in treatment of HF.

Garg V, Frishman WH.

Cardiol Rev. 2013 May-Jun;21(3):155-9. doi: 10.1097/CRD.0b013e318275889c. Review.

PMID:
23018669
19.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
20.

Omecamtiv Mecarbil, a Cardiac Myosin Activator, Increases Ca2+ Sensitivity in Myofilaments With a Dilated Cardiomyopathy Mutant Tropomyosin E54K.

Utter MS, Ryba DM, Li BH, Wolska BM, Solaro RJ.

J Cardiovasc Pharmacol. 2015 Oct;66(4):347-53. doi: 10.1097/FJC.0000000000000286.

PMID:
26065842
Items per page

Supplemental Content

Write to the Help Desk